Literature DB >> 23569998

Elevated alanine aminotransferase activity is not associated with dyslipidemias, but related to insulin resistance and higher disease grades in non-diabetic non-alcoholic fatty liver disease.

Mohammad Ebrahim Ghamar-Chehreh1, Mohsen Amini, Hossein Khedmat, Seyed Moayed Alavian, Fatemeh Daraei, Reza Mohtashami, Reza Hadi, Bent-Al-Hoda Beyram, Saeed Taheri.   

Abstract

OBJECTIVE: To explore demographic and metabolic factors associated with increased alanine aminotransferase (ALT) activity in non-diabetic non-alcoholic fatty liver disease (NAFLD) patients.
METHODS: Overall 372 patients who consecutively attended to Gastroenterology Clinic of Baqiyatallah University of Medical Sciences, Tehran, Iran awere diagnosed as NAFLD entered into analysis. Exclusion criteria were having diabetes mellitus and fasting blood glucose over 126 mg/dL, active hepatitis B virus infection, having hepatitis C virus positive serology, and to be under corticosteroid therapy. ALT levels were considered pathologically high when it was over 30 IU/L for men and over 19 IU/L for women.
RESULTS: Bivariate analyses using t test and chi-square test showed that patients with pathologically augmented ALT levels had significantly higher NAFLD grades in their ultrasonographic evaluations (P=0.003). Moreover, these patients represented significantly higher homeostatic model assessment levels (P=0.003), levels of serum insulin (P=0.002), fasting blood glucose (P<0.001), and uric acid (P=0.02). The prevalence of insulin resistance was also higher in patients with increased serum ALT concentrations. Multifactorial logistic regression models showed that ultrasonographic grading of NAFLD (P=0.027) and insulin resistance (P=0.013) were the only variables significantly associated with abnormal ALT levels.
CONCLUSIONS: This study shows that the associations of increased ALT serum levels in NAFLD patients are different from what are supposed before. By excluding diabetic patients from our population, we find that increased ALT levels are not associated with dyslipidemias but are independently associated with insulin resistance and NAFLD grading on ultrasonographic evaluations. Further studies are needed to confirm our results.

Entities:  

Keywords:  Alanine aminotransferase; Diabetes mellitus; Dyslipidemia; Fasting blood glucose; Insulin resistance; Metabolic factor; Non-alcoholic fatty liver disease; Serum insulin; Ultrasonographic evaluation

Mesh:

Substances:

Year:  2012        PMID: 23569998      PMCID: PMC3609376          DOI: 10.1016/S2221-1691(12)60213-5

Source DB:  PubMed          Journal:  Asian Pac J Trop Biomed        ISSN: 2221-1691


  30 in total

1.  'Liver: an alarm for the heart?'.

Authors:  Seyed-Moayed Alavian
Journal:  Liver Int       Date:  2008-02       Impact factor: 5.828

2.  Shift work aggravates metabolic syndrome development among early-middle-aged males with elevated ALT.

Authors:  Yu-Cheng Lin; Tun-Jen Hsiao; Pau-Chung Chen
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

3.  Healthy range for serum ALT and the clinical significance of "unhealthy" normal ALT levels in the Korean population.

Authors:  Hyun Seok Kang; Soon Ho Um; Yeon Seok Seo; Hyonggin An; Kwang Gyun Lee; Jong Jin Hyun; Eun Sun Kim; Sung Chul Park; Bora Keum; Ji Hoon Kim; Hyung Joon Yim; Yoon Tae Jeen; Hong Sik Lee; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  J Gastroenterol Hepatol       Date:  2011-02       Impact factor: 4.029

4.  Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.

Authors:  F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

5.  Low HDL-cholesterol: a component of the metabolic syndrome only in the presence of fasting hypertriglyceridemia in type 2 diabetic patients.

Authors:  S Bo; P Cavallo-Perin; L Gentile; E Repetti; G Pagano
Journal:  Diabetes Metab       Date:  2001-02       Impact factor: 6.041

6.  Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes.

Authors:  Concetta Irace; Marco Rossetti; Claudio Carallo; Susanna Morano; Viviana Vespertini; Elisabetta Mandosi; Marianna Maranghi; Raffaella Fiorentino; Sebastiano Filetti; Agostino Gnasso
Journal:  Acta Diabetol       Date:  2011-02-09       Impact factor: 4.280

7.  Population-based risk factors and resource utilization for HCC: US perspective.

Authors:  A Sanyal; A Poklepovic; E Moyneur; V Barghout
Journal:  Curr Med Res Opin       Date:  2010-09       Impact factor: 2.580

8.  Hypertriglyceridemic waist phenotype and associated lifestyle factors in a national population of youths: CASPIAN Study.

Authors:  Seyed-Moayed Alavian; Mohammad Esmaeil Motlagh; Gelayol Ardalan; Molouk Motaghian; Amir Hossein Davarpanah; Roya Kelishadi
Journal:  J Trop Pediatr       Date:  2007-12-21       Impact factor: 1.165

Review 9.  Non-alcoholic fatty liver disease pathogenesis: the present and the future.

Authors:  S Petta; C Muratore; A Craxì
Journal:  Dig Liver Dis       Date:  2009-02-14       Impact factor: 4.088

10.  Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

Authors:  M Prashanth; H K Ganesh; M V Vima; M John; T Bandgar; Shashank R Joshi; S R Shah; P M Rathi; A S Joshi; Hemangini Thakkar; P S Menon; N S Shah
Journal:  J Assoc Physicians India       Date:  2009-03
View more
  7 in total

1.  Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population.

Authors:  Minrui Li; Shenghong Zhang; Yanqin Wu; Junzhao Ye; Xu Cao; Jie Liu; Yanhong Sun; Bihui Zhong
Journal:  Dig Dis Sci       Date:  2015-02-17       Impact factor: 3.199

2.  Effect of Vitamin E and Metformin on Fatty Liver Disease in Obese Children- Randomized Clinical Trial.

Authors:  Kobra Shiasi Arani; Abbas Taghavi Ardakani; Razieh Moazami Goudarzi; Hamid Reza Talari; Kamran Hami; Hossein Akbari; Nima Akbari
Journal:  Iran J Public Health       Date:  2014-10       Impact factor: 1.429

Review 3.  Hepatic function and the cardiometabolic syndrome.

Authors:  Nicolas Wiernsperger
Journal:  Diabetes Metab Syndr Obes       Date:  2013-10-10       Impact factor: 3.168

4.  Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran.

Authors:  Atoosa Adibi; Shahab Maleki; Peyman Adibi; Reza Etminani; Silva Hovsepian
Journal:  Adv Biomed Res       Date:  2017-04-17

5.  Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease.

Authors:  Anna E Garcia; Nader Kasim; Robyn A Tamboli; Raul S Gonzalez; Joseph Antoun; Emily A Eckert; Pamela A Marks-Shulman; Julia Dunn; Julia Wattacheril; Taylor Wallen; Naji N Abumrad; Charles Robb Flynn
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

6.  Nonalcoholic fatty liver disease is associated with increased hemoconcentration, thrombocytopenia, and longer hospital stay in dengue-infected patients with plasma leakage.

Authors:  Suhendro Suwarto; Riyanti Astrid Diahtantri; Mohammad Jauharsyah Hidayat; Bing Widjaya
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

7.  Relationship between shift work and liver enzymes: a cross-sectional study based on the Korea National Health and Examination Survey (2007-2015).

Authors:  Hyeongyeong Choi; Hyun-Jeong Oh; Ji-Su Shin; MyeongSeob Lim; Sung-Kyung Kim; Hee-Tae Kang; Sung-Soo Oh; Sang-Baek Koh
Journal:  Ann Occup Environ Med       Date:  2019-07-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.